Connect with us

Headlines

FDA Recalls Online Vision Test

The company was formerly known as Opternative.

mm

Published

on

The Visibly Online Refractive Vision Test has been recalled by the U.S. Food and Drug Administration.

The test by Visibly, formerly known as Opternative, “is being recalled since the firm has not received authorization from FDA to market the product,” according to a notice from the FDA.

The FDA states that the test has had worldwide distribution, including including Arizona, California, Delaware, Florida, Illinois, Missouri, Nevada, New York, Ohio, Pennsylvania, Texas, Washington and Utah.

Eyecare Shenanigans: 2023’s Top Optometry Articles in Invision Magazine
Eyecare Shenanigans

Eyecare Shenanigans: 2023’s Top Optometry Articles in Invision Magazine

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs
INVISION Podcast

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads
INVISION Podcast

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads

Healio.com notes that the FDA sent a warning letter to Opternative in 2017. The news site reports that the company did not respond to a request for comment on the recall.

The American Optometric Association states that in April 2016, it “issued a formal complaint to the FDA that emphasized Opternative’s lack of premarket approval (PMA) prior to marketing. The organization says it “indicated that the test should be removed from the market altogether.”

AOA states that it had concerns about “the potential for inaccurate prescriptions, missed diagnoses of serious and general health conditions, and the creation of a prescription with little input from an eye doctor.”

Advertisement

“Optometrists and other physicians know that eye exams are essential care and that new health technologies must always enhance the doctor-patient relationship and help deliver improved outcomes,” said AOA President Barbara L. Horn, OD. “They must also comply with the law — that’s exactly what the AOA and our state associations have insisted on through the information we provided to the FDA and other agencies in this matter, and we’re proud that it appears to have made a difference.”

The action is a Class 2 recall, meaning the FDA considers it “a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

The FDA explains that recall is “a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective.”

SPONSORED VIDEO

Meet the Next Generation of Smart Glasses

Ray-Ban Meta is now available with a full range of lenses, as a complete pair or edged lens. Prescription orders eligible through select insurance providers, including Eyemed and private pay. The Ray-Ban Meta collection combines iconic design with cutting-edge technology. Capture life’s best moments and livestream to Facebook and Instagram with an upgraded 12 MP camera and five-mic system. Stay connected with hands-free calls and messages. Listen to your favorite tracks through built-in speakers. Spark your creativity, get information and control your glasses with your voice – powered by Meta AI. All while keeping your phone in your pocket. For more information, visit here.

Promoted Headlines

Most Popular